Expanding its platform targeting dysregulating metabolism into the emerging field of metabolic immuno-oncology found Agios Pharmaceuticals Inc. linking up with a familiar ally in Celgene Corp., which plunked down a hefty $200 million in cash up front in a new collaboration. While they were at it, the partners retooled their existing collaboration, crafting what Agios CEO David Schenkein called a "win-win deal," that broadens Celgene's immuno-oncology shots on goal and positions Agios as a commercial player.